Cell. anti-PD1 mAb, 609A. Keywords: Bispecific antibody, PD1, EGFR, Immune checkpoint blockade, Targeted therapy Abbreviations: BsAb, bispecific antibody; EGFR, epidermal growth element receptor; PD1, programed cell death protein 1; PDL1, programed cell death ligand 1; ADCC, antibody-dependent cellular cytotoxicity; PBMC, peripheral blood mononuclear cells; NK cells, natural killer NK cells; DC, dendritic cells; TAM, tumor-associated macrophage; MDSC, myeloid-derived suppressor cells; TKDs, tyrosine kinase domains Abstract We developed a strategy to combine standard targeted therapy with immune checkpoint blockade using a tumor-targeting bispecific antibody (BsAb) to treat solid tumors. The BsAb was designed to simultaneously participate a tumor-associated antigen, epidermal growth element receptor (EGFR), and programed cell death protein 1 (PD1). In addition to its direct anti-tumor activity via EGFR inhibition, the BsAb mediated efficient antibody-dependent cellular cytotoxicity (ADCC) and triggered T cell antitumor im munity through blockade of PD1 from interacting with its counterpart, programed cell death ligand 1 (PDL1). Further, the BsAb exhibited a potent direct tumor cell killing activity in the presence of PBMC, most likely, via activating and, at the same time, literally interesting T cells with tumor cells. Taken collectively, we here illustrate a new strategy in the design and production of novel BsAbs with enhanced restorative effectiveness through both direct tumor growth inhibition and T cell activation via tumor-targeted immune YF-2 checkpoint blockade. Keywords: Bispecific antibody, PD1, EGFR, Immune checkpoint blockade, YF-2 Targeted therapy Abbreviations: BsAb, bispecific antibody; EGFR, epidermal growth element receptor; PD1, programed cell death protein 1; PDL1, programed cell death ligand 1; ADCC, antibody-dependent cellular cytotoxicity; PBMC, peripheral blood mononuclear cells; YF-2 NK cells, natural killer NK cells; DC, dendritic cells; TAM, tumor-associated macrophage; MDSC, myeloid-derived suppressor cells; TKDs, tyrosine kinase domains Intro Tumor growth and metastasis are strongly affected by tumor microenvironment. Within the tumor microenvironment, T cells, B cells, natural killer (NK) cells, tumor-associated macrophage (TAM), dendritic cells (DC), myeloid-derived suppressor cells (MDSC) and additional cells form a dynamic immune network [1,2]. Malignancy cells can dampen, switch and block the anti-tumor activities of immune cells, a mechanism called immune evasion. Programmed cell death protein 1/ programed cell death ligand 1 (PD1/PDL1), an immune checkpoint complex, exploited by many tumors to evade immune system, has been extensively studied. Binding of PD1 YF-2 to PDL1 (CD274, B7-H1) suppresses the function of tumor-infiltrating T-lymphocytes, by inducing apoptosis or turning them into a state of exhaustion [3]. In addition, studies also showed that ligation of PD1 with PDL1 can affect the activities of NK cells, TAMs and DCs as well [4], [5], [6], [7], [8], [9], [10], [11]. In this regard, monoclonal antibodies (mAb) that block PD1/PDL1 connection by focusing on either PD1 or PDL1 have been shown to restore immune reactions in tumor microenvironment, resulting in significant and sometimes, long-lasting anti-tumor activity in clinics for several cancers, including melanoma, lymphoma, non-small cell lung malignancy, gastric and liver cancers [12]. EGFR/HER1 is definitely a member of the epidermal growth element receptor (EGFR) family and plays important roles in development and tumorigenesis, e.g. lung tumors [13,14]. HER receptors are often overexpressed or mutated Itga10 in many tumors and thus are considered as important focuses on for anti-tumor therapy. Activation of HER receptors entails the homo- and hetero-dimerization of the extracellular website of HER receptors (EGFR, HER2, HER3 or HER4) following ligand binding [15,16]. This prospects to the formation of an asymmetric dimer of the intracellular tyrosine kinase domains (TKDs), which results in the allosteric activation and YF-2 trans-phosphorylation of tyrosines in the tail of the TKDs [17]. EGFR activation can activate multiple intracellular signaling pathways, including PLC–PKC, Ras-Raf-MEK, PI3K-Akt-mTOR and JAK2-STAT3 and thus play essential tasks in tumor growth and metastasis [18], [19], [20], [21]. To day, a number of anti-EGFR mAbs and receptor tyrosine kinase inhibitors have been authorized for treatment of multiple cancers, including colorectal, head & throat, and non-small cell lung cancers [22], [23], [24], [25], [26]. Several approaches have been explored to further enhance the restorative efficacy of the anti-PD1/PDL1 and the anti-EGFR antibodies. Novel mAb to additional immune checkpoint targets, for example antagonistic antibodies to LAG3, TIM3 and TIGIT, and agonistic antibodies to CD40, OX40 and 4-1BB, are becoming recognized and developed [27,28]. Anti-EGFR antibody-based bispecific antibodies (BsAb) and antibody-drug conjugates (ADC) will also be being analyzed [29C31]. Recently, combination therapies of two or more tumor-targeting mAbs, for example, anti-HER2 mAbs, trastuzumab and pertuzumab, in breast tumor, or two or more immune checkpoint inhibitor mAbs, for instance, an anti-PD1 mAb (nivolumab) and an anti-CTLA4 mAb (ipilimumab) in melanoma and NSCLC, or others, such as an anti-vascular endothelial growth element (VEGF) mAb (bevacizumab) and an anti-PDL1 mAb.